Congestive heart failure induced by six of the newer antiarrhythmic drugs

Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts.

The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests. The incidence rate ranged from 0.7% with lorcainide to 4.7% with propafenone. Congestive heart failure was present in 167 patients (41%) who underwent 491 drug trials. Congestive failure was induced in 15 (9%) of these 167 patients and involved 19 (3.9%) of the 491 tests. Left ventricular ejection fraction was 20 +/- 8% in patients who developed congestive failure, in contrast to 39 +/- 19% in those who did not (p less than 0.001). It is concluded that each of the six antiarrhythmic drugs examined has the potential to aggravate congestive heart failure in patients with reduced left ventricular ejection fraction or a history of congestive heart failure, but the incidence rate is low and its occurrence unpredictable.

This article has been cited by other articles:

				I. A. Khan Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation J. Am. Coll. Cardiol., February 1, 2001; 37(2): 542 - 547. [Abstract] [Full Text] [PDF]

				A. O. Peralta, R. M. John, W. H. Gaasch, P. I. Taggart, D. T. Martin, and F. J. Venditti The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1404 - 1410. [Abstract] [Full Text] [PDF]

				G. Cice, E. Tagliamonte, L. Ferrara, and A. Iacono Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study Eur. Heart J., August 1, 2000; 21(15): 1259 - 1264. [Abstract] [PDF]

				A.U Khand, A.C Rankin, G.C Kaye, and J.G.F Cleland Systematic review of the management of atrial fibrillation in patients with heart failure Eur. Heart J., April 2, 2000; 21(8): 614 - 632. [Abstract] [PDF]

				S. L. Yong, R. Xu, J. G. McLarnon, A. B. Zolotoy, G. N. Beatch, and M. J. A. Walker RSD1000: A Novel Antiarrhythmic Agent with Increased Potency under Acidic and High-Potassium Conditions J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 236 - 244. [Abstract] [Full Text]

				A. Serdar Fak, H. Tezcan, O. Caymaz, S. Tokay, S. Oktay, and A. Oktay Intravenous Propafenone for Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm: A Randomized, Placebo-controlled, Crossover Study Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 251 - 257. [Abstract] [PDF]